Mar 4, 2024 Cellectar Biosciences Reports High Rate of Complete Remission in Investigator Initiated Phase I Study of Iopofosine in Combination with External Beam Radiotherapy in Recurrent Head and Neck Cancer Learn More
Feb 7, 2024 Cellectar Biosciences to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference Learn More
Jan 30, 2024 Cellectar Biosciences Announces Enrollment of the First Patient in Pediatric High-Grade Gliomas Phase 1b Clinical Study Learn More
Jan 25, 2024 Cellectar Biosciences Announces Tranche A Warrants Fully Exercised, Providing Proceeds of $44.1 Million Learn More